Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
antihistaminics	82	87848-99-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: BW-270C BW-825C acrivastine semprex	a second generation antihistamine Molecular weight: 348.45 Formula: C22H24N2O2 CLOGP: 1.46 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 53.43 ALOGS: -4.54 ROTB: 6 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

BW-270C
BW-825C
acrivastine
semprex

a second generation antihistamine

Molecular weight: 348.45
Formula: C22H24N2O2
CLOGP: 1.46
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 53.43
ALOGS: -4.54
ROTB: 6

Status: OFM

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
24	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.70 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	67 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.31 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	18 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
fu (Fraction unbound in plasma)	0.16 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value
kinase-safety-class	ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EGFR,EIF2AK3,ERBB2,GRK2,IKBKB,ITK,MAP2K6,MAPK10,MAPK7,MAPKAPK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,STK33,SYK,TEK,TGFBR1	29
kinase-selectivity-class	ACVR2B,AXL,BRAF,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,MAP2K6,MAPK7,SIK2,STK33,TEK,TGFBR1,TTK,ZAP70	18
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
March 25, 1994	FDA	AUXILIUM PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Asthma-chronic obstructive pulmonary disease overlap syndrome	361.92	35.25	75	4069	4824	90619479
Total lung capacity increased	360.08	35.25	75	4069	4946	90619357
Hypomania	338.40	35.25	79	4065	8818	90615485
Jaundice cholestatic	328.88	35.25	79	4065	9964	90614339
Sarcoidosis	303.78	35.25	75	4069	10598	90613705
Nasal polyps	302.35	35.25	75	4069	10805	90613498
Schizophrenia	297.86	35.25	79	4065	14835	90609468
Rhinitis allergic	274.70	35.25	76	4068	16709	90607594
Cardiac murmur	264.11	35.25	75	4069	18119	90606184
Bronchiectasis	248.94	35.25	75	4069	22255	90602048
Psychotic disorder	244.24	35.25	80	4064	31150	90593153
Blood bilirubin increased	222.05	35.25	81	4063	43389	90580914
Lung neoplasm malignant	217.63	35.25	69	4075	24204	90600099
Hepatotoxicity	210.53	35.25	79	4065	45763	90578540
Cholelithiasis	200.11	35.25	79	4065	52427	90571876
Chronic obstructive pulmonary disease	177.32	35.25	80	4064	73749	90550554
Gastrooesophageal reflux disease	107.11	35.25	76	4068	166261	90458042
Wheezing	85.05	35.25	77	4067	238003	90386300
Hepatic enzyme increased	74.77	35.25	87	4057	360649	90263654
Oedema peripheral	72.32	35.25	73	4071	257842	90366461
Condition aggravated	70.23	35.25	109	4035	595436	90028867
Pneumonia	54.23	35.25	101	4043	637958	89986345

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Spleen congestion	43.28	37.40	7	632	350	42620346
Pharyngeal paraesthesia	43.06	37.40	8	631	901	42619795

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Total lung capacity increased	369.19	30.58	76	4674	5036	110579513
Asthma-chronic obstructive pulmonary disease overlap syndrome	352.83	30.58	76	4674	6268	110578281
Hypomania	337.62	30.58	80	4670	10130	110574419
Jaundice cholestatic	309.15	30.58	80	4670	14528	110570021
Sarcoidosis	301.07	30.58	76	4674	12503	110572046
Nasal polyps	297.43	30.58	76	4674	13124	110571425
Rhinitis allergic	279.01	30.58	77	4673	17845	110566704
Schizophrenia	277.33	30.58	80	4670	21746	110562803
Cardiac murmur	250.52	30.58	76	4674	24552	110559997
Bronchiectasis	221.13	30.58	76	4674	36417	110548132
Psychotic disorder	214.38	30.58	81	4669	50856	110533693
Lung neoplasm malignant	203.16	30.58	70	4680	33772	110550777
Hepatotoxicity	193.78	30.58	80	4670	63320	110521229
Cholelithiasis	193.75	30.58	80	4670	63342	110521207
Blood bilirubin increased	186.29	30.58	82	4668	75890	110508659
Chronic obstructive pulmonary disease	155.10	30.58	81	4669	109077	110475472
Gastrooesophageal reflux disease	112.89	30.58	79	4671	179897	110404652
Hepatic enzyme increased	89.51	30.58	88	4662	320804	110263745
Wheezing	88.48	30.58	79	4671	255151	110329398
Oedema peripheral	63.09	30.58	74	4676	328586	110255963
Condition aggravated	54.57	30.58	106	4644	734730	109849819
Pharyngeal paraesthesia	43.02	30.58	13	4737	4119	110580430
Pneumonia	40.81	30.58	105	4645	876609	109707940
Nausea	38.36	30.58	128	4622	1235562	109348987
Salpingo-oophorectomy bilateral	36.63	30.58	7	4743	314	110584235
Bone density abnormal	35.20	30.58	11	4739	3892	110580657
Spleen congestion	33.55	30.58	7	4743	492	110584057
Blood immunoglobulin E	33.38	30.58	5	4745	49	110584500

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	R06AX18	RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Other antihistamines for systemic use
FDA MoA	N0000000190	Histamine H1 Receptor Antagonists
MeSH PA	D006633	Histamine Antagonists
MeSH PA	D006634	Histamine H1 Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018494	Histamine Agents
MeSH PA	D039563	Histamine H1 Antagonists, Non-Sedating
FDA EPC	N0000175587	Histamine-1 Receptor Antagonist
CHEBI has role	CHEBI:37955	H<small><sub>1</sub></small>-receptor antagonist

Related Drugs by ATC class:

R06AX Other antihistamines for systemic use 26 drugs

antazoline astemizole azatadine azelastine bamipine bilastine cyproheptadine deptropine desloratadine ebastine epinastine fexofenadine show all 26 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Vasomotor rhinitis	indication	8229003	DOID:4730
Allergic rhinitis	indication	61582004
Nasal discharge	indication	64531003
Nasal congestion	indication	68235000
Sneezing	indication	76067001
Common cold	indication	82272006	DOID:10459
Seasonal allergic rhinitis	indication	367498001
Allergic conjunctivitis	indication	473460002	DOID:11204
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Coronary arteriosclerosis	contraindication	53741008	DOID:3393
Diabetes mellitus	contraindication	73211009	DOID:9351
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Hypertensive urgency	contraindication	443482000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.78	acidic
pKa2	9.42	Basic
pKa3	1.55	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST	IC50	7.16	WOMBAT-PK	CHEMBL
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN				WOMBAT-PK
Histamine H1 receptor	GPCR		HRH1_CAVPO		IC50	5.21	CHEMBL

External reference:

ID	Source
4020857	VUID
N0000179060	NUI
D02760	KEGG_DRUG
19959	RXNORM
C0054340	UMLSCUI
CHEBI:83168	CHEBI
CHEMBL1224	ChEMBL_ID
DB09488	DRUGBANK_ID
C043648	MESH_SUPPLEMENTAL_RECORD_UI
5284514	PUBCHEM_CID
5548	INN_ID
A20F9XAI7W	UNII
4130	MMSL
d03753	MMSL
4020857	VANDF
003921	NDDF
320813002	SNOMEDCT_US
391716003	SNOMEDCT_US
A20F9XAI7W	INXIGHT DRUGS

Pharmaceutical products:

None

Ask DrugCentral

Try a sample question

acrivastine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: